- Home
- ASPN vs PRAX Comparison
ASPN vs PRAX Comparison
Compare ASPN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPN
- PRAX
- Stock Information
- Founded
- ASPN 2001
- PRAX 2015
- Country
- ASPN United States
- PRAX United States
- Employees
- ASPN N/A
- PRAX N/A
- Industry
- ASPN RETAIL: Building Materials
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- ASPN Consumer Discretionary
- PRAX Health Care
- Exchange
- ASPN Nasdaq
- PRAX Nasdaq
- Market Cap
- ASPN 570.6M
- PRAX 599.7M
- IPO Year
- ASPN 2014
- PRAX 2020
- Fundamental
- Price
- ASPN $6.28
- PRAX $43.81
- Analyst Decision
- ASPN Strong Buy
- PRAX Strong Buy
- Analyst Count
- ASPN 10
- PRAX 11
- Target Price
- ASPN $21.78
- PRAX $114.73
- AVG Volume (30 Days)
- ASPN 1.7M
- PRAX 296.2K
- Earning Date
- ASPN 08-06-2025
- PRAX 08-12-2025
- Dividend Yield
- ASPN N/A
- PRAX N/A
- EPS Growth
- ASPN N/A
- PRAX N/A
- EPS
- ASPN N/A
- PRAX N/A
- Revenue
- ASPN $436,921,000.00
- PRAX $8,122,000.00
- Revenue This Year
- ASPN N/A
- PRAX N/A
- Revenue Next Year
- ASPN $24.31
- PRAX N/A
- P/E Ratio
- ASPN N/A
- PRAX N/A
- Revenue Growth
- ASPN 51.90
- PRAX 270.02
- 52 Week Low
- ASPN $4.16
- PRAX $26.70
- 52 Week High
- ASPN $33.15
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- ASPN 54.44
- PRAX 61.35
- Support Level
- ASPN $6.14
- PRAX $43.44
- Resistance Level
- ASPN $6.54
- PRAX $46.93
- Average True Range (ATR)
- ASPN 0.28
- PRAX 2.58
- MACD
- ASPN 0.02
- PRAX 0.35
- Stochastic Oscillator
- ASPN 62.26
- PRAX 73.38
About ASPN Aspen Aerogels Inc.
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.